Akron Biotechnology, which provides novel technologies for cell therapy and regenerative medicine discovery, development and commercialization, will move into a new, larger facility that will significantly increasing space for its R&D and manufacturing operations in Boca Raton, Florida.
“The expansion will play an increasingly important role in the company’s growth and allow Akron to more strongly meet the growing demand for validated products and processes for the regenerative medicine industry,” said Claudia Zylberberg, PhD, Founder/CEO of Akron Biotech. “Our commitment to providing our customers with quality products and comprehensive solutions to meet their specific needs has resulted in consistent growth, making Akron a key player in the regenerative medicine/biotechnology arena.”
While the company's headquarters and operations have already moved to the new address, the construction of its new state-of-the-art biotechnology facility is still under way. Once completed, the facility will house over 12,000 sq. ft. of laboratory and manufacturing space. It will focus on the translation and commercialization of innovative discoveries as well as manufacturing for both research and clinical use.
According to the firm, Akron's new facility will be one of the largest of its kind in Florida and will produce regulated products on a large scale for academic and industry clients from both the United States and abroad. The facility will enhance the company’s current capacity with several class 10,000 and class 100 clean rooms -- which will accommodate small and large scale manufacturing -- and cell culture labs for bioassay development and validation.
The augmented capacity will further expand Akron's proven expertise in cGMP product manufacturing and process development, providing its customers with greater flexibility in manufacturing and enhanced environmental control as well as increased support for documentation and compliance, the company said.